Intermittent Claudication Market Research Report: Market size, Industry outlook, Market Forecast, Demand Analysis,Market Share, Market Report 2018-2023
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Intermittent Claudication Market
Intermittent Claudication Market: By Drug Type (ALD-301, DVC1-0101, K-134, LT-0101, PLX-PAD, Tirasemtiv), By Treatment Process (Medication therapies, Revascularization) and Geography - Forecast(2018 - 2023)
Report Code : HCR 0229
Updated Date: 16 May, 2018  

1. Intermittent Claudication – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Intermittent Claudication – Market Forces
   4.1. Drivers
      4.1.1. Increasing population with life style, smoking, hypertension, diabetes and high cholesterol related diseases
   4.2. Restraints
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Intermittent Claudication – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Intermittent Claudication  Market, By Drug Type
   6.1. ALD-301
   6.2. DVC1-0101
   6.3. K-134
   6.4. LT-0101
   6.5. PLX-PAD
   6.6. Tirasemtiv
7. Intermittent Claudication  Market, By Treatment Process
   7.1. Medication therapies
   7.2. Revascularization
8. Intermittent Claudication  Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Intermittent Claudication – Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles (By- Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
   10.1. Cytokinetics Inc.
   10.2. DNAVEC Corporation
   10.3. Nuo Therapeutics Inc.
   10.4. Kowa Company Ltd.
   10.5. LTT Bio-Pharma Co. Ltd.
   10.6. Pluristem Therapeutics Inc.
   10.7. ID Pharma Co., Ltd.
   10.8. Bayer AG
   10.9. Cipla Inc.
   10.10. Cadila Pharmaceuticals Ltd.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Expert Insights
Please select Licence
Single User Licence:
US $5250
Corporate User Licence:
US $7250
Related Reports
0px;">Scroll